Proposed biomarkers include PD-L1 expression, tumor-infiltrating lymphocytes, and tumor mutational burden, but we are still far from being able to select the patients with cerebral disease that would benefit the most from ICIs. This evidence concerns the gene CD274 and neoplasm.